These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31702003)

  • 41. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
    Michos ED; Tuttle KR
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
    [No Abstract]   [Full Text] [Related]  

  • 42. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure.
    Daghlas I; Karhunen V; Ray D; Zuber V; Burgess S; Tsao PS; Lynch JA; Lee KM; Voight BF; Chang KM; Baker EH; Damrauer SM; Howson JMM; Vujkovic M; Gill D
    J Am Heart Assoc; 2021 Jul; 10(13):e020331. PubMed ID: 34184541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
    Niessner A; Tamargo J; Koller L; Saely CH; Schmidt TA; Savarese G; Wassmann S; Rosano G; Ceconi C; Torp-Pedersen C; Kaski JC; Kjeldsen KP; Agewall S; Walther T; Drexel H; Lewis BS
    Eur Heart J; 2018 Jun; 39(24):2274-2281. PubMed ID: 29126266
    [No Abstract]   [Full Text] [Related]  

  • 46. Insulin initiation status of primary care physicians in Turkey, barriers to insulin initiation and knowledge levels about insulin therapy: A multicenter cross-sectional study.
    Ates E; Set T; Saglam Z; Tekin N; Karatas Eray I; Yavuz E; Sahin MK; Selcuk EB; Cadirci D; Cubukcu M
    Prim Care Diabetes; 2017 Oct; 11(5):430-436. PubMed ID: 28579057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
    Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
    Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perceptions of general practitioners on initiation and intensification of type 2 diabetes injectable therapies. A quantitative study in the United Kingdom.
    Sterzi D; Auziere S; Glah D; Markert Jensen M
    Prim Care Diabetes; 2017 Jun; 11(3):241-247. PubMed ID: 28395938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
    Fadini GP; Zatti G; Baldi I; Bottigliengo D; Consoli A; Giaccari A; Sesti G; Avogaro A;
    Diabetes Obes Metab; 2018 Jul; 20(7):1781-1786. PubMed ID: 29516612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Liraglutide on Arterial Inflammation Assessed as [
    Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
    Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update.
    Li B; Salata K; de Mestral C; Hussain MA; Aljabri BA; Lindsay TF; Verma S; Al-Omran M
    Ann Vasc Surg; 2019 Jul; 58():166-173.e4. PubMed ID: 30771465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.
    Vergès B; Avignon A; Bonnet F; Catargi B; Cattan S; Cosson E; Ducrocq G; Elbaz M; Fredenrich A; Gourdy P; Henry P; Lairez O; Leguerrier AM; Monpère C; Moulin P; Vergès-Patois B; Roussel R; Steg G; Valensi P; ;
    Arch Cardiovasc Dis; 2012 Apr; 105(4):239-53. PubMed ID: 22808525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
    Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
    Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reported underuse of risk scores in patients with acute coronary syndromes without persistent ST elevations in clinical practice: results of a survey of the ALKK study group.
    Zeymer U; Schneider S; Zahn R; Andresen D
    Clin Res Cardiol; 2014 Jan; 103(1):83-4. PubMed ID: 24264474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.